Omega Diagnostics Group PLC Result of Open Offer (1019D)
01 Marzo 2022 - 1:00AM
UK Regulatory
TIDMODX
RNS Number : 1019D
Omega Diagnostics Group PLC
01 March 2022
THIS ANNOUNCEMENT AND THE INFORMATION IN IT, IS NOT FOR
PUBLICATION, RELEASE OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN
WHOLE OR IN PART, IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA,
NEW ZEALAND, JAPAN, THE REPUBLIC OF SOUTH AFRICA OR ANY OTHER
JURISDICTION WHERE TO DO SO MIGHT CONSTITUTE A VIOLATION OR BREACH
OF ANY APPLICABLE LAW OR REGULATION.
FURTHER, THIS ANNOUNCEMENT IS FOR INFORMATION PURPOSES ONLY AND
IS NOT AN OFFER OF SECURITIES IN ANY JURISDICTION.
THE INFORMATION CONTAINED WITHIN THIS ANNOUNCEMENT IS DEEMED BY
THE COMPANY TO CONSTITUTE INSIDE INFORMATION. UPON THE PUBLICATION
OF THIS ANNOUNCEMENT VIA THE REGULATORY INFORMATION SERVICE, THIS
INSIDE INFORMATION IS NOW CONSIDERED TO BE IN THE PUBLIC
DOMAIN.
OMEGA DIAGNOSTICS GROUP PLC
("Omega" or the "Company" or the "Group")
Result of Open Offer
Omega (AIM: ODX), the specialist medical diagnostics company
focused on industry-leading Health & Nutrition and Global
Health (CD4 and COVID-19) products, today announces the results of
its Open Offer.
On 11 February 2022, Omega announced its intention to raise
gross proceeds of up to GBP7 million by way of a Placing,
Subscription and Open Offer (together the "Fundraising"), all at an
issue price of 5 pence per New Ordinary Share.
The Open Offer closed for acceptances at 11:00 a.m. on 28
February 2022. The Company has received valid acceptances from
Qualifying Shareholders in respect of their Basic Entitlements in
respect of 6,468,652 New Ordinary Shares and has also received
applications from Qualifying Shareholders under the Excess
Application Facility in respect of 3,085,559 New Ordinary Shares.
In aggregate this totals 9,554,211 New Ordinary Shares,
representing approximately 23.5 per cent. of the Open Offer Shares.
Accordingly, Qualifying Shareholders who have validly applied for
Open Offer Shares will receive their full Basic Entitlements as
well as those applied for under the Excess Application
Facility.
Accordingly, a total of 109,554,211 New Ordinary Shares will be
issued at the Issue Price (subject to the conditions noted below),
of which, 98,700,000 New Ordinary Shares will be issued pursuant to
the Placing, 1,300,000 New Ordinary Shares will be issued pursuant
to the Subscription and 9,554,211 New Ordinary Shares will be
issued pursuant to the Open Offer (the "Open Offer Shares"). This
brings the gross proceeds of the Fundraising to GBP5.48 million
before expenses.
General Meeting
The Fundraising remains conditional on the approval by
Shareholders of the Resolutions at the Company's General Meeting to
be held on 7 March 2022 (or any adjournment thereof), the
satisfaction of certain conditions in the Placing Agreement and
Admission of the New Ordinary Shares to trading on AIM occurring at
or before 8.00 a.m. on 8 March 2022 (or such later date as the
Company and finnCap may agree, being not later than 8.00 a.m. on 31
March 2022).
The Company will announce the results of the General Meeting as
soon as practicable after the meeting concludes.
Capitalised terms not otherwise defined in the text of this
announcement have the meanings given to them in the Company's
circular dated 11 February 2022.
For further information, please contact:
Enquiries
Omega Diagnostics Group PLC www.omegadiagnostics.com
Jag Grewal, Chief Executive via Walbrook PR
Officer
Chris Lea, Chief Financial Officer
finnCap Ltd Tel: 020 7220 0500
Geoff Nash/Edward Whiley/George Dollemore
(Corporate Finance)
Alice Lane/ Charlotte Sutcliffe
(ECM)
Walbrook PR Limited Tel: 020 7933 8780 or omega@walbrookpr.com
Paul McManus Mob: 07980 541 893
Lianne Applegarth Mob: 07584 391 303
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
ROIUWVBRUSUUUAR
(END) Dow Jones Newswires
March 01, 2022 02:00 ET (07:00 GMT)
Omega Diagnostics (LSE:ODX)
Gráfica de Acción Histórica
De Mar 2024 a Abr 2024
Omega Diagnostics (LSE:ODX)
Gráfica de Acción Histórica
De Abr 2023 a Abr 2024